enGene to Host KOL Webinar on October 15, 2026
Financial Post ·
Community Key Opinion Leaders (KOLs) to present on real-world clinical decision making in high-risk non-muscle invasive bladder cancer (NMIBC) Additional discussion to focus on preclinical data supporting incorporation of a surfactant bladder rinse plus detalimogene voraplasmid into clinical development BOSTON & MONTREAL — enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral […]
Read More